Sacubitril and valsartan 4 mg/mL oral suspension
- Concentration
- 4 mg/mL
- Vehicles named
- Ora-Plus, Ora-Sweet
- Container
- glass bottle
The label's instructions
2.4 Preparation of Oral Suspension Using Tablets ENTRESTO oral suspension can be substituted at the recommended tablet dosage in patients unable to swallow tablets. ENTRESTO 800 mg/200 mL oral suspension can be prepared in a concentration of 4 mg/mL (sacubitril/valsartan 1.96/2.04 mg/mL). Use ENTRESTO 49/51 mg tablets in the preparation of the suspension. To make an 800 mg/200 mL (4 mg/mL) oral suspension, transfer eight tablets of ENTRESTO 49/51 mg film-coated tablets into a mortar. Crush the tablets into a fine powder using a pestle. Add 60 mL of Ora-Plus ® into the mortar and triturate gently with pestle for 10 minutes, to form a uniform suspension. Add 140 mL of Ora-Sweet ® SF into mortar and triturate with pestle for another 10 minutes, to form a uniform suspension. Transfer the entire contents from the mortar into a clean 200 mL amber colored PET or glass bottle. Place a press-in bottle adapter and close the bottle with a child resistant cap. The oral suspension can be stored for up to 15 days. Do not store above 25°C (77°F) and do not refrigerate. Shake before each use. * Ora-Sweet SF ® and Ora-Plus ® are registered trademarks of Paddock Laboratories, Inc.
Quoted verbatim from the Dosage and Administration section of the FDA label for ENTRESTO, version 25, effective 2026-07-06. Open the label on DailyMed. 34 current labels for this drug carry these instructions.
Storage and beyond-use date
| Storage | BUD | Basis |
|---|---|---|
| Room temperature | 15 days | Storage and duration as the FDA label states them. |
- “The oral suspension can be stored for up to 15 days. Do not store above 25°C (77°F) and do not refrigerate.”
Only the storage conditions the source covers are listed. Use the BUD assistant for other cases. The BUD may not be later than any component's expiration date. Verify against the current official USP chapter.
Ingredient checks
No FDA compounding list or NIOSH flags for the active ingredient.
Source
FDA label (ENTRESTO), Dosage and Administration.
For licensed clinicians. Use with clinical judgment.